National Breast Cancer Month Spotlights Awareness Efforts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

WASHINGTON--Zeneca Pharmaceuticals and its National Breast Cancer Awareness Month (NBCAM) co-sponsors have presented First Lady Hillary Rodham Clinton with the Government Leadership Award for her outstanding initiative in launching efforts to educate women about mammography.

WASHINGTON--Zeneca Pharmaceuticals and its National Breast CancerAwareness Month (NBCAM) co-sponsors have presented First LadyHillary Rodham Clinton with the Government Leadership Award forher outstanding initiative in launching efforts to educate womenabout mammography.

Special awards were given to three sets of "partners"who have played pivotal roles in breast cancer awareness: formerFirst Lady Betty Ford and her daughter Susan Ford Bales; NancyBrinker and, posthumously, her sister, Susan G. Komen; and HarveyKushner and, posthumously, his wife, Rose.

Community outreach programs honored were Carilion Health System,Roanoke, Va; Emory University School of Medicine; and HartfordHospital.

Awards for achievement in providing employees access to breastcancer screening and education at the worksite went to MetrolinaOutreach Mammography, Charlotte, NC, and Tri Valley Growers, SanFrancisco.

In the print media category, Oncology Times received an awardfor its stories on the National Surgical Adjuvant Breast and BowelProject.

Primary Care & Cancer, under the editorial directionof James McCarthy and published by PRR, Inc. (which also publishesthe journal Oncology and Oncol-ogy News International), was honoredfor its Breast Self-Examination Guide, and John Gentile, Jr.,president of PRR, won an Awareness Achievement Award (see photographbelow), which he accepted on behalf of the entire staff.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.